NCT07912710
China HEalthy Aging and Dementia Study (HEAD)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Mild cognitive impairment (MCI)
Timeframe: Baseline and approximately annual follow-up assessments (up to 50 years)
Dementia
Timeframe: Baseline and approximately annual follow-up assessments (up to 50 years)
Mild cognitive impairment due to Alzheimer's disease (MCI due to AD)
Timeframe: Baseline and approximately annual follow-up assessments (up to 50 years)
Dementia due to Alzheimer's disease (AD dementia)
Timeframe: Baseline and approximately annual follow-up assessments (up to 50 years)
Mini-Mental State Examination (MMSE) total score
Timeframe: Baseline and approximately annual follow-up assessments (up to 50 years)
Montreal Cognitive Assessment (MoCA) total score
Timeframe: Baseline and approximately annual follow-up assessments (up to 50 years)
Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score
Timeframe: Baseline and approximately annual follow-up assessments (up to 50 years)
Secondary (27)
Auditory Verbal Learning Test (AVLT) learning score
Auditory Verbal Learning Test (AVLT) short-delay recall score
Auditory Verbal Learning Test (AVLT) long-delay recall score
Forward Digit Span Test score
Backward Digit Span Test score
Show 22 moreShow less
Trail Making Test Part A (TMT-A) completion time
Trail Making Test Part B (TMT-B) completion time
Clock Drawing Test (CDT) total score
Verbal Fluency Test (VFT) total score
Plasma amyloid-β 1-42 (Aβ1-42) concentration
Plasma amyloid-β 1-40 (Aβ1-40) concentration
Plasma amyloid-β 1-42/1-40 ratio (Aβ1-42/Aβ1-40)
Plasma phosphorylated tau 181 (p-tau181) concentration
Plasma phosphorylated tau 217 (p-tau217) concentration
Plasma total tau (t-tau) concentration
Plasma neurofilament light chain (NfL) concentration
Plasma glial fibrillary acidic protein (GFAP) concentration
Cerebrospinal fluid amyloid-β 1-42 (Aβ1-42) concentration
Cerebrospinal fluid amyloid-β 1-40 (Aβ1-40) concentration
Cerebrospinal fluid amyloid-β 1-42/1-40 ratio (Aβ1-42/Aβ1-40)
Cerebrospinal fluid phosphorylated tau 181 (p-tau181) concentration
Cerebrospinal fluid phosphorylated tau 217 (p-tau217) concentration
Cerebrospinal fluid total tau (t-tau) concentration
Cerebrospinal fluid neurofilament light chain (NfL) concentration
Cerebrospinal fluid glial fibrillary acidic protein (GFAP) concentration
Regional brain atrophy assessed by structural MRI
Cerebral amyloid-β burden assessed by PET
Arms and interventions
China HEAD Community Cohort
A nationwide, multicenter, community-based prospective cohort of individuals aged 50-79 years from eastern, northern, southern, western, and central regions of China, established using standardized protocols to ensure harmonized data collection and quality control across participating centers.
China HEAD Familial Sub-cohort
A nationwide, multicenter prospective sub-cohort of individuals aged 18 years or older with a family history of Alzheimer's disease, established using standardized protocols to ensure harmonized data collection and quality control across participating centers.
Sites
30 sites in 1 country